JP2004536105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536105A5 JP2004536105A5 JP2003510059A JP2003510059A JP2004536105A5 JP 2004536105 A5 JP2004536105 A5 JP 2004536105A5 JP 2003510059 A JP2003510059 A JP 2003510059A JP 2003510059 A JP2003510059 A JP 2003510059A JP 2004536105 A5 JP2004536105 A5 JP 2004536105A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- goat
- antibody
- serum composition
- goat serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283707 Capra Species 0.000 claims 15
- 210000002966 serum Anatomy 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 3
- 239000002609 medium Substances 0.000 claims 3
- 238000004113 cell culture Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 claims 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 claims 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 230000036436 anti-hiv Effects 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0116151.2 | 2001-07-02 | ||
| GB0116151A GB0116151D0 (en) | 2001-07-02 | 2001-07-02 | Therapeutic agent |
| GB0128638.4 | 2001-11-29 | ||
| GB0128638A GB0128638D0 (en) | 2001-11-29 | 2001-11-29 | Therapeutic agent |
| GBGB0201896.8A GB0201896D0 (en) | 2002-01-28 | 2002-01-28 | Treatment |
| GB0201896.8 | 2002-01-28 | ||
| GB0207509.1 | 2002-03-28 | ||
| GB0207509A GB0207509D0 (en) | 2002-03-28 | 2002-03-28 | Therapeutic agent |
| PCT/GB2002/003037 WO2003004049A2 (en) | 2001-07-02 | 2002-07-02 | Use of polyclonal anti-hiv goat serum as a therapeutic agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009091136A Division JP5128539B2 (ja) | 2001-07-02 | 2009-04-03 | 治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004536105A JP2004536105A (ja) | 2004-12-02 |
| JP2004536105A5 true JP2004536105A5 (enExample) | 2005-09-29 |
| JP5014562B2 JP5014562B2 (ja) | 2012-08-29 |
Family
ID=27447968
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003510059A Expired - Fee Related JP5014562B2 (ja) | 2001-07-02 | 2002-07-02 | 治療薬 |
| JP2009091136A Expired - Fee Related JP5128539B2 (ja) | 2001-07-02 | 2009-04-03 | 治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009091136A Expired - Fee Related JP5128539B2 (ja) | 2001-07-02 | 2009-04-03 | 治療薬 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20100291102A1 (enExample) |
| EP (1) | EP1404367B1 (enExample) |
| JP (2) | JP5014562B2 (enExample) |
| KR (2) | KR20040030786A (enExample) |
| CN (1) | CN100423776C (enExample) |
| AT (1) | ATE478681T1 (enExample) |
| AU (1) | AU2002317285B2 (enExample) |
| BR (1) | BR0210772A (enExample) |
| CA (1) | CA2452986C (enExample) |
| DE (1) | DE60237447D1 (enExample) |
| DK (1) | DK1404367T3 (enExample) |
| EA (1) | EA013517B1 (enExample) |
| HU (1) | HU228957B1 (enExample) |
| IL (2) | IL159682A0 (enExample) |
| MX (1) | MXPA04000147A (enExample) |
| NZ (1) | NZ530393A (enExample) |
| PL (1) | PL216741B1 (enExample) |
| WO (1) | WO2003004049A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003064472A2 (en) * | 2002-01-28 | 2003-08-07 | Aimsco Limited | Treatment of ms with goat serum |
| GB0201896D0 (en) * | 2002-01-28 | 2002-03-13 | Ice Biolog Ltd | Treatment |
| AU2002317285B2 (en) * | 2001-07-02 | 2007-05-24 | Aimsco Limited | Use of polyclonal anti-HIV goat serum as a therapeutic agent |
| ES2339035T3 (es) | 2004-04-05 | 2010-05-14 | Aimsco Limited | Tratamiento de enfermedades. |
| KR101235723B1 (ko) * | 2004-07-08 | 2013-02-21 | 아임스코 리미티드 | 약제 |
| GB0415359D0 (en) * | 2004-07-08 | 2004-08-11 | Aimsco Ltd | Medicament |
| GB0502083D0 (en) * | 2005-02-02 | 2005-03-09 | Aimsco Ltd | Bioactive compounds |
| GB0508153D0 (en) * | 2005-04-22 | 2005-06-01 | Aimsco Ltd | Therapeutic agent |
| GB0509052D0 (en) * | 2005-05-04 | 2005-06-08 | Aimsco Ltd | Combination therapy |
| GB0600202D0 (en) * | 2006-01-06 | 2006-02-15 | Aimsco Ltd | Treatment of HIV |
| CA3016948A1 (en) * | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| US8734852B2 (en) * | 2011-11-30 | 2014-05-27 | Manu Chaudhary | Parenteral controlled release formulations of NSAID's |
| WO2014001749A1 (en) | 2012-06-25 | 2014-01-03 | Aimsco Limited | Formulation comprising crh and alpha - 2 - immunoglobulin |
| UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
| RU2710567C1 (ru) | 2017-01-31 | 2019-12-27 | Иллюмина, Инк. | Устройства для текучих сред и способы изготовления таких устройств |
| CN117538549A (zh) * | 2023-09-27 | 2024-02-09 | 上海交通大学医学院附属瑞金医院 | 一种评估血浆置换清除dsa临床疗效的预测体系 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
| JPH02237935A (ja) * | 1989-03-10 | 1990-09-20 | Bio Kagaku Kenkyusho:Kk | エイズ処置剤 |
| CZ186897A3 (cs) | 1994-12-23 | 1998-03-18 | Laboratoires Om S. A. | Použití molekul, schopných vázat MHC-II nebo napodobujících MHC-II pro výrobu farmaceutického prostředku |
| WO1996040941A1 (en) * | 1995-06-07 | 1996-12-19 | Connaught Laboratories Limited | Chimeric antibodies for delivery of antigens to selected cells of the immune system |
| WO1997002839A1 (en) * | 1995-07-13 | 1997-01-30 | Gkc Research, Inc. | Viral suppression, treatment and prevention of viral infections |
| US6448000B1 (en) * | 1996-04-15 | 2002-09-10 | Vanderbilt University | Mammalian genes involved in viral infection and tumor suppression |
| GB9619894D0 (en) * | 1996-09-24 | 1996-11-06 | Celltech Therapeutics Ltd | Pharmaceutical products |
| WO2000012560A1 (en) * | 1998-08-28 | 2000-03-09 | Dendreon Corporation | Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| CA2270600A1 (en) * | 1999-05-03 | 2000-11-03 | Infectio Recherche Inc. | Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania |
| CN1191861C (zh) * | 1999-05-24 | 2005-03-09 | 三共株式会社 | 含有抗Fas抗体的药物组合物 |
| KR20020020730A (ko) * | 1999-06-09 | 2002-03-15 | 오트리브 데이비스 더블유 | Ｂ-세포를 표적하는 항체를 이용한 자가면역질환의 면역치료 |
| WO2001060156A1 (en) * | 2000-02-14 | 2001-08-23 | Gary R. Davis, M.D., L.L.C. | Neutralizing antibody and immunomodulatory enhancing compositions |
| EP1156060B1 (en) * | 2000-05-12 | 2007-06-27 | GPC Biotech AG | Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells |
| EP1156062A1 (en) * | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| AU2001275696A1 (en) * | 2000-07-21 | 2002-02-05 | Ice Biologics Limited | Therapeutic agent |
| AU2002317285B2 (en) * | 2001-07-02 | 2007-05-24 | Aimsco Limited | Use of polyclonal anti-HIV goat serum as a therapeutic agent |
-
2002
- 2002-07-02 AU AU2002317285A patent/AU2002317285B2/en not_active Ceased
- 2002-07-02 US US10/482,399 patent/US20100291102A1/en not_active Abandoned
- 2002-07-02 HU HU0401392A patent/HU228957B1/hu not_active IP Right Cessation
- 2002-07-02 DK DK02745565.8T patent/DK1404367T3/da active
- 2002-07-02 DE DE60237447T patent/DE60237447D1/de not_active Expired - Lifetime
- 2002-07-02 EP EP02745565A patent/EP1404367B1/en not_active Expired - Lifetime
- 2002-07-02 WO PCT/GB2002/003037 patent/WO2003004049A2/en not_active Ceased
- 2002-07-02 KR KR10-2004-7000049A patent/KR20040030786A/ko not_active Ceased
- 2002-07-02 MX MXPA04000147A patent/MXPA04000147A/es active IP Right Grant
- 2002-07-02 JP JP2003510059A patent/JP5014562B2/ja not_active Expired - Fee Related
- 2002-07-02 CA CA2452986A patent/CA2452986C/en not_active Expired - Fee Related
- 2002-07-02 PL PL367828A patent/PL216741B1/pl unknown
- 2002-07-02 IL IL15968202A patent/IL159682A0/xx not_active IP Right Cessation
- 2002-07-02 NZ NZ530393A patent/NZ530393A/en not_active IP Right Cessation
- 2002-07-02 EA EA200400134A patent/EA013517B1/ru not_active IP Right Cessation
- 2002-07-02 KR KR1020097007314A patent/KR100938590B1/ko not_active Expired - Fee Related
- 2002-07-02 AT AT02745565T patent/ATE478681T1/de active
- 2002-07-02 BR BR0210772-4A patent/BR0210772A/pt not_active IP Right Cessation
- 2002-07-02 CN CNB028171705A patent/CN100423776C/zh not_active Expired - Fee Related
-
2009
- 2009-04-03 JP JP2009091136A patent/JP5128539B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-09 US US13/315,830 patent/US20120100156A1/en not_active Abandoned
-
2012
- 2012-08-30 IL IL221708A patent/IL221708A/en not_active IP Right Cessation
-
2013
- 2013-02-08 US US13/763,435 patent/US20130230600A1/en not_active Abandoned
-
2015
- 2015-07-07 US US14/793,716 patent/US20160002320A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536105A5 (enExample) | ||
| Romagnani et al. | Role of interleukins in induction and regulation of human IgE synthesis | |
| CA2452986A1 (en) | Use of polyclonal anti-hiv goat serum as a therapeutic agent | |
| Dhiman et al. | NK1. 1+ cells and IL-22 regulate vaccine-induced protective immunity against challenge with Mycobacterium tuberculosis | |
| JP2012508163A5 (enExample) | ||
| KR102118559B1 (ko) | 면역-관련 및 염증성 질환의 치료 | |
| Haverkamp et al. | Nontuberculous mycobacterial infections in children with inborn errors of the immune system | |
| US20170071944A1 (en) | Modulators of toll-like receptors for the treatment of hiv | |
| Sebastiani et al. | Nickel-specific CD4+ and CD8+ T cells display distinct migratory responses to chemokines produced during allergic contact dermatitis | |
| RU2018118575A (ru) | Способы культивирования клеток и наборы и устройство для них | |
| JP2006519228A5 (ja) | 抗原に対し霊長類を免疫寛容化する抗体の使用法 | |
| JP2017079785A5 (enExample) | ||
| JP2018537962A5 (enExample) | ||
| JP2013501814A5 (enExample) | ||
| Burns et al. | Presence, function, and regulation of IL‐17F‐expressing human CD4+ T cells | |
| WO2020057541A8 (en) | Anti-ifnar1 antibodies for treating autoimmune diseases | |
| WO2005044854A3 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| Baldassari et al. | Daclizumab: development, clinical trials, and practical aspects of use in multiple sclerosis | |
| AU621830B2 (en) | Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease | |
| JP2003516940A5 (enExample) | ||
| JP2006312640A (ja) | Ｔ細胞活性化 | |
| JP2012504555A (ja) | 自己免疫疾患を治療するためにｂヘルパーｔ細胞を減少させる方法 | |
| Jeger-Madiot et al. | Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infection | |
| JP2004523538A5 (enExample) | ||
| JP2003102471A5 (enExample) |